NCT07777341

Brief Summary

Previous studies suggest that both RW and red grape juice (RGJ) have beneficial properties upon risk factors and cardiovascular events. However, the effects of grape polyphenols on metabolomics in men are still poorly understood. Recent advances in mass spectroscopy allowed substantial advances in the analysis of molecular signatures of several diseases. Therefore, the objective of this study is to evaluate the impact of RGJ on plasma metabolomics in patients with chronic coronary disease (CAD). This is a crossover, prospective, randomized and controlled study, with two 3-week interventions: 1. daily consumption of RGJ (400 mL) and 2. total abstention from foods rich in polyphenols. Plasma metabolomics will be performed by gas chromatography (GC)/mass spectroscopy (MS) by (Prof. Labate, Department of Plant Genetics, ESALQ). The sample will consist of 50 patients with chronic CAD. aged between 46 and 69 years. The inclusion and exclusion criteria were defined to achieve homogeneity of the group and avoid interference. The central hypothesis of this study is that RGJ will exert effects upon pathways involved in lipids, carbohidrates and energy production, contributing to the understanding of the mechanisms of action of polyphenols on cardiovascular health, without the risks associated with alcohol.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
22mo left

Started Jul 2026

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress11%
Jul 2026Aug 2028

Study Start

First participant enrolled

July 10, 2026

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

August 17, 2026

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 20, 2026

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 10, 2028

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 10, 2028

Last Updated

August 28, 2026

Status Verified

August 1, 2026

Enrollment Period

1.9 years

First QC Date

August 17, 2026

Last Update Submit

August 25, 2026

Conditions

Keywords

Coronary Artery Disease (CAD)Red Grape JuiceMetabolomics

Outcome Measures

Primary Outcomes (1)

  • Plasma Metabolomics Changes

    Change in plasma metabolomic profile after red grape juice consumption compared with the abstinence period.

    From enrollment to the end of treatment at 10 weeks

Study Arms (2)

Red Juice/ Abstention

EXPERIMENTAL

Group 1(Red Juice/ Abstention) will first consume 400 mL of red grape juice per day, five days per week, for three weeks, followed by a period of abstinence from polyphenol-rich foods.

Other: Red Grape Juice

Abstention/ Red Juice

EXPERIMENTAL

Group 2 (Abstention/ Red Juice) will follow the same interventions in the opposite order, beginning with the abstinence period and then consuming red grape juice.

Other: Red Grape Juice

Interventions

Participants will undergo two 3-week intervention periods in random order: daily consumption of 400 mL of red grape juice and a control period involving complete abstinence from polyphenol-rich foods.

Abstention/ Red JuiceRed Juice/ Abstention

Eligibility Criteria

Age46 Years - 69 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age between 46 and 69 years.
  • Established chronic coronary artery disease, defined by at least one of the following:
  • Acute myocardial infarction occurring more than 30 days before enrollment;
  • Angiographic evidence of ≥50% stenosis in one or more epicardial coronary arteries;
  • Previous percutaneous coronary intervention (PCI);
  • Previous coronary artery bypass grafting (CABG).
  • BMI \<30 kg/m².
  • Absence of:
  • Angina symptoms;
  • Dyspnea.

You may not qualify if:

  • Use of antibiotics within 8 weeks before study enrollment.
  • Heart failure, NYHA functional class ≥ II.
  • Renal insufficiency, defined as creatinine clearance \<30 mL/min, calculated using the Cockcroft-Gault equation.
  • Hepatic insufficiency, defined by:
  • Thrombocytopenia;
  • Reduced serum albumin;
  • Prolonged prothrombin time.
  • Cancer.
  • Inflammatory bowel disease.
  • Obstructive biliary disease.
  • History of digestive tract surgery, including:
  • Cholecystectomy;
  • Gastrectomy;
  • Colectomy.
  • Diabetes mellitus.
  • +11 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Incor - Instituto do Coração HCFMUSP

São Paulo, São Paulo, 05403-000, Brazil

RECRUITING

Related Publications (1)

  • Ghaedi E , Moradi S , Aslani Z , Kord-Varkaneh H , Miraghajani M , Mohammadi H . Effects of grape products on blood lipids: a systematic review and dose-response meta-analysis of randomized controlled trials. Food Funct. 2019 Oct 16;10(10):6399-6416. doi: 10.1039/c9fo01248f.

    PMID: 31517353BACKGROUND

MeSH Terms

Conditions

Coronary Artery Disease

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Study Officials

  • Antonio Carlos Palandri Chagas

    Incor - Instituto do Corção HCFMUSP

    STUDY CHAIR

Central Study Contacts

Protásio Lemos da Luz

CONTACT

Michelle Aparecida Pereira Nistico

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor Doctor

Study Record Dates

First Submitted

August 17, 2026

First Posted

August 20, 2026

Study Start

July 10, 2026

Primary Completion (Estimated)

June 10, 2028

Study Completion (Estimated)

August 10, 2028

Last Updated

August 28, 2026

Record last verified: 2026-08

Data Sharing

IPD Sharing
Will not share

Locations